Nintedanib Cf

Nintedanib, the active ingredient in Nintedanib Cf, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients.

GNH USA supplies Nintedanib Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic agent used in chronic fibrotic lung disorders.

Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays functional deterioration.

Nintedanib may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Diarrhea: frequent, often mild to moderate. - Nausea: may be accompanied by vomiting. - Abdominal pain or discomfort. - Decreased appetite and unintended weight loss. - Elevated liver enzymes (ALT, AST).

Serious or Rare Side Effects: - Severe liver injury or hepatitis. - Significant bleeding events, especially when combined with anticoagulants. - Cardiovascular events such as myocardial infarction. - Gastrointestinal perforations. - Severe hypersensitivity reactions, including skin rash and angioedema.

Before initiating therapy, clinicians should consider several safety measures.

Monitor liver function: obtain baseline and periodic ALT/AST assessments. Assess bleeding risk: avoid concomitant use with strong anticoagulants unless necessary. Evaluate cardiovascular status: caution in patients with recent myocardial infarction. Pregnancy and lactation: use only if potential benefit outweighs unknown risks. Dose adjustment in hepatic impairment: consider reduced exposure in moderate impairment. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nintedanib interacts with several drug classes that may alter its exposure or increase adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): markedly increase nintedanib plasma levels. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may increase exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - P‑gp inhibitors (e.g., verapamil): modestly raise concentrations. - NSAIDs or antiplatelet agents: monitor for additive bleeding risk.